Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
Abstract Introduction Amyloid‐related imaging abnormalities (ARIA) are a common, dose‐dependent effect of amyloid‐targeting antibodies, strongly associated with the apolipoprotein E (APOE) ε4 allele. Methods We describe the clinical course and management of a 66‐year‐old white male (APOE ε4/ε4) enro...
Main Authors: | Lawren VandeVrede, Daniel M Gibbs, Mary Koestler, Renaud La Joie, Peter A. Ljubenkov, Karine Provost, David Soleimani‐Meigooni, Amelia Strom, Elena Tsoy, Gil D. Rabinovici, Adam L. Boxer |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
Subjects: | |
Online Access: | https://doi.org/10.1002/dad2.12101 |
Similar Items
-
Tau pathology in cognitively normal older adults
by: Jacob Ziontz, et al.
Published: (2019-12-01) -
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
by: Jeffrey Cummings, et al.
Published: (2021-05-01) -
Reducing fibrosis progression of biliary atresia by continuous administration of aducanumab at low dose: A potential treatment
by: Chi Hang Lui, V., et al.
Published: (2022) -
Aducanumab: evidence from clinical trial data and controversies
by: Rajesh R Tampi, et al.
Published: (2021-10-01) -
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
by: Martin Tolar, et al.
Published: (2020-08-01)